Tamarack Advisers, LP recently filed their 13F report for the second quarter of 2022, which ended on 2022-06-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
5050 AVENIDA ENCINAS CARLSBAD, CA 92008
As of the latest 13F report, the guru’s equity portfolio contained 39 stocks valued at a total of $172.00Mil. The top holdings were CI(9.64%), LNTH(9.58%), and CERS(6.14%).
According to GuruFocus data, these were Tamarack Advisers, LP’s top five trades of the quarter.
United Therapeutics Corp
The guru established a new position worth 30,000 shares in NAS:UTHR, giving the stock a 4.1% weight in the equity portfolio. Shares traded for an average price of $202.92 during the quarter.
On 08/17/2022, United Therapeutics Corp traded for a price of $221.66 per share and a market cap of $10.09Bil. The stock has returned 11.12% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, United Therapeutics Corp has a price-earnings ratio of 16.79, a price-book ratio of 2.31, a EV-to-Ebitda ratio of 9.88 and a price-sales ratio of 5.92.
The price-to-GF Value ratio is 1.18, earning the stock a GF Value rank of 3.
Medtronic PLC
The guru sold out of their 75,000-share investment in NYSE:MDT. Previously, the stock had a 3.94% weight in the equity portfolio. Shares traded for an average price of $101.48 during the quarter.
On 08/17/2022, Medtronic PLC traded for a price of $95.31 per share and a market cap of $126.64Bil. The stock has returned -24.47% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Medtronic PLC has a price-earnings ratio of 25.56, a price-book ratio of 2.41, a EV-to-Ebitda ratio of 15.97 and a price-sales ratio of 4.06.
The price-to-GF Value ratio is 0.82, earning the stock a GF Value rank of 9.
Laboratory Corp of America Holdings
The guru established a new position worth 25,000 shares in NYSE:LH, giving the stock a 3.4% weight in the equity portfolio. Shares traded for an average price of $248.37 during the quarter.
On 08/17/2022, Laboratory Corp of America Holdings traded for a price of $259.15 per share and a market cap of $23.43Bil. The stock has returned -15.16% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Laboratory Corp of America Holdings has a price-earnings ratio of 12.42, a price-book ratio of 2.26, a price-earnings-to-growth (PEG) ratio of 0.65, a EV-to-Ebitda ratio of 8.34 and a price-sales ratio of 1.56.
The price-to-GF Value ratio is 0.98, earning the stock a GF Value rank of 6.
Amgen Inc
The guru established a new position worth 24,000 shares in NAS:AMGN, giving the stock a 3.39% weight in the equity portfolio. Shares traded for an average price of $245 during the quarter.
On 08/17/2022, Amgen Inc traded for a price of $253.15 per share and a market cap of $135.42Bil. The stock has returned 12.00% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Amgen Inc has a price-earnings ratio of 21.47, a price-book ratio of 55.97, a price-earnings-to-growth (PEG) ratio of 4.57, a EV-to-Ebitda ratio of 13.61 and a price-sales ratio of 5.33.
The price-to-GF Value ratio is 0.97, earning the stock a GF Value rank of 7.
Merck & Co Inc
Tamarack Advisers, LP reduced their investment in NYSE:MRK by 80,000 shares. The trade had a 3.11% impact on the equity portfolio. During the quarter, the stock traded for an average price of $88.55.
On 08/17/2022, Merck & Co Inc traded for a price of $90.59 per share and a market cap of $229.49Bil. The stock has returned 19.74% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Merck & Co Inc has a price-earnings ratio of 13.86, a price-book ratio of 5.32, a price-earnings-to-growth (PEG) ratio of 1.82, a EV-to-Ebitda ratio of 10.88 and a price-sales ratio of 4.03.
The price-to-GF Value ratio is 0.86, earning the stock a GF Value rank of 9.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
